Company
Headquarters: Eden Prairie, MN, United States
Employees: 2
| Company | Market Cap (USD) |
|---|---|
| Abbott | $178.02 B |
| Stryker Corporation | $126.48 B |
| Boston Scientific Corporation | $112.32 B |
| Medtronic | $98.95 B |
| Edwards Lifesciences Corporation | $55.63 B |
| Company | Market Cap (USD) |
|---|---|
| Lilly | $808.65 B |
| Novo Nordisk | $622.07 B |
| UnitedHealth Group | $450.89 B |
| Johnson & Johnson | $350.63 B |
| Merck | $318.75 B |
ProUroCare Medical Inc. engages in developing products for the detection and characterization of male urological prostate disease. It offers the ProUroScan System, a prostate imaging system that aids the physician in documenting abnormalities in the prostate that have been previously detected by a digital rectal exam. The company has licensing, development, and commercialization agreements with Artann Laboratories Inc. for its ProUroScan System. ProUroCare Medical Inc. was founded in 1999 and is based in Eden Prairie, Minnesota.
Top 1-year algo backtest: +265.99%
$10,000 in October 2023 would now be $36,599 by following this algorithm daily at market close.
Use AI to boost your investing & swing trading, now!
Try Disfold DeepFinance FREE
ProUroCare Medical, Inc. has the following listings and related stock indices.
Stock: OTC: PUMD wb_incandescent